Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Aishwarya, Saraswat"'
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 35, Iss 3, Pp 102292- (2024)
Patients suffering from BRAF mutant melanoma have tumor recurrence within merely 7 months of treatment with a potent BRAF inhibitor (BRAFi) like vemurafenib. It has been proven that diverse molecular pathways driving BRAFi resistance converge to acti
Externí odkaz:
https://doaj.org/article/24f54a3de91540fbbc9a798eb30be707
Autor:
Deepak Kumar Sahel, Lalitkumar K. Vora, Aishwarya Saraswat, Saurabh Sharma, Jasmin Monpara, Anisha A. D'Souza, Deepakkumar Mishra, Kamatham Pushpa Tryphena, Satoru Kawakita, Shahid Khan, Mohd Azhar, Dharmendra Kumar Khatri, Ketan Patel, Raghu Raj Singh Thakur
Publikováno v:
Advanced Science, Vol 10, Iss 25, Pp n/a-n/a (2023)
Externí odkaz:
https://doaj.org/article/8f703b7274924d53b4f38a7d01b4fd1d
Publikováno v:
Heliyon, Vol 8, Iss 1, Pp e08702- (2022)
This research deals with the development of asialoglycoprotein receptors (ASGPR) directed nanoliposomes incorporating a novel BRD4 (Bromodomain-containing protein 4) protein-targeted PROTAC (Proteolysis Targeting Chimera), ARV-825 (ARV) (GALARV), and
Externí odkaz:
https://doaj.org/article/c06bc4448d5d46efbe3ca4422c9ccaf6
Publikováno v:
Nanomedicine. 18:169-190
Nanocarriers passively accumulate in solid tumors through irregular wide fenestrations in neovasculature and increased retention due to poor lymphatic drainage, a phenomenon termed the enhanced permeation and retention (EPR) effect. Although several
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0165921a9b5d17931b817fd40333cb3
https://doi.org/10.2217/nnm-2022-0257
https://doi.org/10.2217/nnm-2022-0257
Autor:
Yige Fu, Aishwarya Saraswat, Zenghui Wei, Manas Yogendra Agrawal, Vikas V. Dukhande, Sandra E. Reznik, Ketan Patel
Publikováno v:
Pharmaceutics, Vol 13, Iss 7, p 1005 (2021)
A novel treatment strategy by co-targeting c-Myc and tumor stroma was explored in vemurafenib-resistant melanoma. BRD4 proteolysis targeting chimera (ARV-825) and nintedanib co-loaded PEGylated nanoliposomes (ARNIPL) were developed to incorporate a s
Externí odkaz:
https://doaj.org/article/c3edc51cc9e54d0a8d8965a4cd2cc24c
Autor:
Aishwarya Saraswat, Ketan Patel
Gene therapy using plasmid DNA (pDNA) is well-explored for variety of genetic diseases. However, its susceptibility to enzymatic degradation desires an optimal delivery system for efficient cellular uptake, transfection, and stability in vivo. Non-vi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3e9350b409755d70c1cdf9a5c9ec47c
https://doi.org/10.21203/rs.3.rs-2649244/v1
https://doi.org/10.21203/rs.3.rs-2649244/v1
Publikováno v:
Cancers; Volume 15; Issue 1; Pages: 182
Being the fourth most fatal malignancy worldwide, pancreatic cancer is on track to become the second leading cause of cancer-related deaths in the United States by 2030. Gemcitabine is a first-line chemotherapeutic agent for pancreatic ductal adenoca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::013cde170959414b390be4814917751b
Publikováno v:
Nanomedicine. 16:1081-1095
Aim: To develop novel cationic liposomes as a nonviral gene delivery vector for the treatment of rare diseases, such as Lafora disease – a neurodegenerative epilepsy. Materials & methods: DLinDMA and DOTAP liposomes were formulated and characterize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35cd6a19ed246a064a9b1bd59151c9b3
https://doi.org/10.2217/nnm-2020-0477
https://doi.org/10.2217/nnm-2020-0477
Publikováno v:
Nanomedicine. 15:1761-1777
Aim: To explore the anticancer activity of a novel BRD4 protein degrader ARV-825 (ARV) and its nanoformulation development (ARV-NP) for treatment of pancreatic cancer. Materials & methods: ARV-NP were prepared using nanoprecipitation method and chara
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f79f8adfe3968feaa30b9d8d9b7090f
https://doi.org/10.2217/nnm-2020-0156
https://doi.org/10.2217/nnm-2020-0156
Publikováno v:
International journal of pharmaceutics. 626
Fascioliasis, a common parasitic infection observed in the pediatric patient population, is a leading cause of concern in countries with poor/unhealthy water resources. To treat this condition first line agent such as triclabendazole (TBZ) has been t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86377190895c9dcb2a8b3c50f43fcb4a
https://pubmed.ncbi.nlm.nih.gov/36067920
https://pubmed.ncbi.nlm.nih.gov/36067920